Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Korsana Biosciences, Inc.
Report date November 21, 2024 · Filed November 25, 2024
Jointly reported with Slate Path Capital LP
Section 16 reporting ended · disclosed 2024-11-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, no par valueSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2024-11-21 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-11-21 · Sale · Disposed 357,880 · Balance 0 F1: The number of shares reported herein reflect the one-for-twenty reverse stock split effected by the Issuer on May 15, 2023. F2: The securities to which this filing relates were held by certain funds (the "Slate Path Funds"). Slate Path Capital LP (the "Investment Manager"), a Delaware limited partnership acts as the investment manager of the Slate Path Funds. Mr. David Greenspan serves as the managing member of Jades GP, LLC, a Delaware limited liability company and the general partner of the Investment Manager. The filing of this statement shall not be deemed an admission that either Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: The number of shares reported herein reflect the one-for-twenty reverse stock split effected by the Issuer on May 15, 2023.
F2: The securities to which this filing relates were held by certain funds (the "Slate Path Funds"). Slate Path Capital LP (the "Investment Manager"), a Delaware limited partnership acts as the investment manager of the Slate Path Funds. Mr. David Greenspan serves as the managing member of Jades GP, LLC, a Delaware limited liability company and the general partner of the Investment Manager. The filing of this statement shall not be deemed an admission that either Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 21, 2024 Filed Nov 25, 2024 21:05 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | SaleCommon Stock, no par value | 357,880 | $1.55 | $555,107.67 |
DisclosureSEC source: 0000902664-24-006775 · ownership.xml · nonDerivative · entry 1 Slate Path Capital LP · CIK 0001559706 · 10% owner Greenspan David Gerald · CIK 0001820641 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · shares: The number of shares reported herein reflect the one-for-twenty reverse stock split effected by the Issuer on May 15, 2023. F2 · ownership.nature: The securities to which this filing relates were held by certain funds (the "Slate Path Funds"). Slate Path Capital LP (the "Investment Manager"), a Delaware limited partnership acts as the investment manager of the Slate Path Funds. Mr. David Greenspan serves as the managing member of Jades GP, LLC, a Delaware limited liability company and the general partner of the Investment Manager. The filing of this statement shall not be deemed an admission that either Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 20:05 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | PurchaseCommon Stock, no par value | 961,538 | $3.12 | $2,999,998.56 |
DisclosureSEC source: 0000902664-21-003032 · ownership.xml · nonDerivative · entry 1 Slate Path Capital LP · CIK 0001559706 · 10% owner Greenspan David Gerald · CIK 0001820641 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 7,157,601 F1 · ownership.nature: The securities to which this filing relates are held by Slate Path Master Fund LP (the "Master Fund"), a Cayman Islands exempted limited partnership. Slate Path Capital LP (the "Investment Manager"), a Delaware limited partnership acts as the investment manager of the Master Fund. Mr. David Greenspan serves as the managing member of Jades GP, LLC, a Delaware limited liability company and the general partner of the Investment Manager. The filing of this statement shall not be deemed an admission that either Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.